{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:36:32Z","timestamp":1790742992794,"version":"4.1.0"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1097\/ico.0b013e318243f69d","type":"journal-article","created":{"date-parts":[[2012,4,24]],"date-time":"2012-04-24T22:32:29Z","timestamp":1335306749000},"page":"950-952","source":"Crossref","is-referenced-by-count":26,"title":["Tacrolimus Ointment 0.03% for Treatment of Refractory Childhood Phlyctenular Keratoconjunctivitis"],"prefix":"10.1097","volume":"31","author":[{"given":"George D.","family":"Kymionis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vardhaman P.","family":"Kankariya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios A.","family":"Kontadakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-19-20210204","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/S0021-5155(99)00185-9","article-title":"Phlyctenular eye disease: a reappraisal.","volume":"44","author":"Rohatgi","year":"2000","journal-title":"Jpn J Ophthalmol"},{"key":"R2-19-20210204","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/BF00202779","article-title":". Immunocytological study of phlyctenular eye disease.","volume":"10","author":"Abu el Asrar","year":"1987","journal-title":"Int Ophthalmol"},{"key":"R3-19-20210204","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/0002-9394(75)90620-0","article-title":"Corneal perforation in nontuberculous (staphylococcal) phlyctenular keratoconjunctivitis.","volume":"79","author":"Ostler","year":"1975","journal-title":"Am J Ophthalmol"},{"key":"R4-19-20210204","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1177\/106002809402800414","article-title":"Tacrolimus, a new immunosuppressanta review of the literature.","volume":"28","author":"Hooks","year":"1994","journal-title":"Ann Pharmacother"},{"key":"R5-19-20210204","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2165\/00044011-200626050-00001","article-title":"Comparison of the efficacy and safety of 0.1 tacrolimus ointment with topical corticosteroids in adult patients with atopic dermatitis: review of randomised, double-blind clinical studies conducted in Japan.","volume":"26","author":"Nakagawa","year":"2006","journal-title":"Clin Drug Investig"},{"key":"R6-19-20210204","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1055\/s-2001-18665","article-title":". FK 506 ointment 0.1a new therapeutic option for atopic blepharitis. Clinical trial with 14 patients.","volume":"218","author":"Mayer","year":"2001","journal-title":"Klin Monbl Augenheilkd"},{"key":"R7-19-20210204","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0002-9394(02)01982-7","article-title":"Topical tacrolimus treatment of atopic eyelid disease.","volume":"135","author":"Rikkers","year":"2003","journal-title":"Am J Ophthalmol"},{"key":"R8-19-20210204","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jaci.2003.10.065","article-title":". Vernal keratoconjunctivitis: results of a novel therapy with 0.1 topical ophthalmic FK-506 ointment.","volume":"113","author":"Vichvanond","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"R9-19-20210204","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1097\/01.ico.0000127484.46584.f6","article-title":". Treatment of atopic eyelid disease using topical tacrolimus following corticosteroid discontinuation in a patient with open-angle glaucoma.","volume":"23","author":"Kymionis","year":"2004","journal-title":"Cornea"},{"key":"R10-19-20210204","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/01.ico.0000151507.49565.6e","article-title":"Topical tacrolimus ointment for treatment of refractory anterior segment inflammatory disorders.","volume":"24","author":"Joseph","year":"2005","journal-title":"Cornea"},{"key":"R11-19-20210204","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1080\/02713680802149115","article-title":". Topical tacrolimus 0.03 ointment for intractable allergic conjunctivitis: an open-label pilot study.","volume":"33","author":"Attax-Fox","year":"2008","journal-title":"Curr Eye Res"},{"key":"R12-19-20210204","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.ophtha.2007.07.025","article-title":". Therapeutic effects of tacrolimus ointment for refractory ocular surface inflammatory diseases.","volume":"115","author":"Miyazaki","year":"2008","journal-title":"Ophthalmology"},{"key":"R13-19-20210204","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/ICO.0b013e318159afbb","article-title":". Tacrolimus ointment 0.03 in the eye for treatment of giant papillary conjunctivitis.","volume":"27","author":"Kymionis","year":"2008","journal-title":"Cornea"},{"key":"R14-19-20210204","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1097\/ICO.0b013e3181d83875","article-title":". Topical tacrolimus ointment for treatment of intractable atopic keratoconjunctivitis: a case report and review of the literature.","volume":"30","author":"Garcia","year":"2011","journal-title":"Cornea"},{"key":"R15-19-20210204","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1093\/ndt\/15.12.1916","article-title":"Clinical and mechanistic differences between FK-506 (tacrolimus) and cyclosporine A.","volume":"15","author":"Almawi","year":"2000","journal-title":"Nephrol Dial Transplant"},{"key":"R16-19-20210204","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ajo.2005.08.035","article-title":". Topical cyclosporine A in severe steroid-dependent childhood phlyctenular keratoconjunctivitis.","volume":"141","author":"Doan","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"R17-19-20210204","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.clindermatol.2009.04.001","article-title":"Malignancy concerns of topical calcineurin inhibitors for atopic dermatitis: facts and controversies.","volume":"28","author":"Thaci","year":"2010","journal-title":"Clin Dermatol"},{"key":"R18-19-20210204","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1517\/14740330902969441","article-title":"Long-term safety of tacrolimus ointment in atopic dermatitis.","volume":"8","author":"Remitz","year":"2009","journal-title":"Expert Opin Drug Saf"},{"key":"R19-19-20210204","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/sj.jid.5700622","article-title":". Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis.","volume":"127","author":"Arellano","year":"2007","journal-title":"J Invest Dermatol"},{"key":"R21-19-20210204","doi-asserted-by":"crossref","first-page":"54","DOI":"10.2340\/00015555-0167","article-title":". Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children.","volume":"87","author":"Remitz","year":"2007","journal-title":"Acta Derm Venereol"}],"container-title":["Cornea"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/ICO.0b013e318243f69d","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T19:33:48Z","timestamp":1621884828000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00003226-201208000-00019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/ico.0b013e318243f69d","relation":{},"ISSN":["0277-3740"],"issn-type":[{"value":"0277-3740","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]}}}